These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24613490)

  • 1. A proposed definition of the 'activity' of surface sites on lactose carriers for dry powder inhalation.
    Grasmeijer F; Frijlink HW; de Boer AH
    Eur J Pharm Sci; 2014 Jun; 56():102-4. PubMed ID: 24613490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
    de Boer AH; Chan HK; Price R
    Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physico-chemical aspects of lactose for inhalation.
    Kou X; Chan LW; Steckel H; Heng PW
    Adv Drug Deliv Rev; 2012 Mar; 64(3):220-32. PubMed ID: 22123598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactose as a carrier for inhalation products: breathing new life into an old carrier. Preface.
    Marriott C; Frijlink HW
    Adv Drug Deliv Rev; 2012 Mar; 64(3):217-9. PubMed ID: 22146699
    [No Abstract]   [Full Text] [Related]  

  • 8. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress of dry powder inhalation of proteins and peptides].
    Zhou JY; Zhang L; Mao SR
    Yao Xue Xue Bao; 2015 Jul; 50(7):814-23. PubMed ID: 26552141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of carrier surface fines on dry powder inhalation formulations.
    Boshhiha AM; Urbanetz NA
    Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking carrier morphology to the powder mechanics of adhesive mixtures for dry powder inhalers via a blend-state model.
    Rudén J; Frenning G; Bramer T; Thalberg K; An J; Alderborn G
    Int J Pharm; 2019 Apr; 561():148-160. PubMed ID: 30825556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
    Dickhoff BH; de Boer AH; Lambregts D; Frijlink HW
    Int J Pharm; 2006 Dec; 327(1-2):17-25. PubMed ID: 16920287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between surface coverage ratio and powder mechanics of binary adhesive mixtures for dry powder inhalers.
    Rudén J; Frenning G; Bramer T; Thalberg K; Alderborn G
    Int J Pharm; 2018 Apr; 541(1-2):143-156. PubMed ID: 29454905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative carriers in dry powder inhaler formulations.
    Rahimpour Y; Kouhsoltani M; Hamishehkar H
    Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder inhalers: a brief overview of the drug detachment techniques.
    Mehta PP
    Ther Deliv; 2020 Mar; 11(3):139-143. PubMed ID: 31914863
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
    Le VN; Hoang Thi TH; Robins E; Flament MP
    Int J Pharm; 2012 Mar; 424(1-2):44-9. PubMed ID: 22207163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.